Loading...
•
Sep 30, 2023
Glaukos Q3 2023 Earnings Report
Glaukos' third quarter results for 2023 reflected strong execution of global commercial strategies and pipeline advancement.
Key Takeaways
Glaukos Corporation reported a 10% increase in net sales to $78.0 million for Q3 2023, with glaucoma net sales up 9% and corneal health net sales up 12%. The company raised its 2023 net sales guidance to $307 million to $310 million.
Net sales reached $78.0 million, a 10% increase year-over-year.
Glaucoma net sales were $58.3 million, up 9% compared to the previous year.
Corneal Health net sales increased by 12% year-over-year, totaling $19.7 million.
Gross margin was approximately 76%, with a non-GAAP gross margin of about 83%.
Revenue by Segment
Forward Guidance
The company expects 2023 net sales to be in the range of $307 million to $310 million based on the latest foreign currency exchange rates.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...